Immunotherapy
Distinguishing the Mechanisms of Tumoral Immune Response and Cutaneous Adverse Events
Checkpoint inhibitor (CPI) therapy has revolutionized cancer treatment, but generates immune-related adverse events (irAEs) that commonly include cutaneous effects. I hypothesize that the tumor response is mechanistically distinct from associated…
Loss of Effective Antigen Presentation in Melanoma and Treatment Failure
Loss of effective presentation of tumor antigens by melanoma may drive immunotherapy resistance. We will use multiplex immunofluorescence to map antigen presentation at single-cell resolution across whole slides, and correlate…
Investigation of Dermatologic Toxicity from Immune Checkpoint Blockade in Advanced Malignancies
Advanced malignancies are increasingly being treated with immune checkpoint inhibitors, which can lead to immune-related adverse events (irAEs), including those in the skin. This project will investigate key clinical, pathologic,…
Identifying Molecular Determinants of Prognosis in Advanced Squamous Cell Carcinoma
Immunotherapy is a crucial treatment for advanced squamous cell cancers that cannot be cured by surgery alone. But it works only half of the time, and we do not know…